Exact Mass: 351.1583
Exact Mass Matches: 351.1583
Found 32 metabolites which its exact mass value is equals to given mass value 351.1583,
within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error
0.0002 dalton.
Aniflorine
Phenylalanyltryptophan
Phenylalanyltryptophan is a dipeptide composed of phenylalanine and tryptophan. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. H-Phe-Trp-OH (Phenylalanyltryptophan) is an endogenous metabolite[1]. H-Phe-Trp-OH (Phenylalanyltryptophan) is an endogenous metabolite[1].
Tryptophyl-Phenylalanine
Tryptophyl-Phenylalanine is a dipeptide composed of tryptophan and phenylalanine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.
Phe-TRP
A dipeptide formed from L-phenylalanine and L-tryptophan residues.
TRP-Phe
A dipeptide formed from L-tryptophan and L-phenylalanine residues.
moquizone
C78276 - Agent Affecting Digestive System or Metabolism > C66913 - Cholagogues or Choleretic Agents
N-[(2-Methyl-1H-benzimidazol-1-yl)acetyl]-L-phenylalanine
N-(2-aminophenyl)-1-butyl-4-hydroxy-2-oxo-3-quinolinecarboxamide
N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-2-(2,3,5-trimethylphenoxy)acetamide
4-[(1-methyl-2-oxo-4-quinolinyl)oxy]-N-(4-methyl-2-pyridinyl)butanamide
(E)-N-cyclohexyl-3-(4-nitrophenyl)-N-pyridin-2-ylprop-2-enamide
N-[2-(cyclohexen-1-yl)ethyl]-2-(4-oxochromeno[4,3-c]pyrazol-1-yl)acetamide
4-[5-(4-methoxyphenyl)-3-isoxazolyl]-N-(2-pyridinylmethyl)butanamide
N-[(2-methoxyphenyl)methyl]-2-methyl-3-prop-2-enoxy-6-indazolecarboxamide
1-butyl-4-hydroxy-N-(3-methyl-2-pyridinyl)-2-oxo-3-quinolinecarboxamide
1-[(2S,3S)-2-(hydroxymethyl)-6-[oxo(2-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-1-yl]ethanone
1-[(2S,3R)-2-(hydroxymethyl)-6-[oxo(2-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-1-yl]ethanone
1-[(2R,3R)-2-(hydroxymethyl)-6-[oxo(2-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-1-yl]ethanone
1-Hydroxy-5-methoxy-3-methyl-6-[[7-(3-methyl-1,3-butadienyl)-1H-indole-3-yl]methyl]pyrazine-2(1H)-one
NAB-14
NAB-14 is a potent, selective, orally active and non-competitive GluN2C/2D antagonists with an IC50 of 580 nM for GluN1/GluN2D. NAB-14 shows >800-fold selective for recombinant GluN2C and GluN2D over GluN2A and GluN2B. NAB-14 can cross the blood-brain-barrier[1].
